Schedule 13G ownership disclosure
EVAXION BIOTECH A/S
American Depositary Shares, each representing fifty Ordinary Shares, DKK 0.25 nominal value per share · CUSIP: 29970R204
Event date: 2025-01-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Merck & Co., Inc.
Shares: 63,004,142.00 · Class: 19.96%
- Merck Sharp & Dohme LLC
Shares: 63,004,142.00 · Class: 19.96%
- Merck Global Health Innovation Fund, LLC
Shares: 63,004,142.00 · Class: 19.96%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001104659-25-008629
- Form type
- SCHEDULE 13G/A
- Filer
- Evaxion Biotech A/S
- CIK
- CIK 1828253
- Filed
- Feb 03, 2025
- Reporting period
- Jan 31, 2025
- Description
- Schedule 13G beneficial ownership